CoChat

Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies

Open access
Zhang, Jun, Xu, Ji-Hong, Qu, Qian-Qin, Zhong, Guo-Qing · 2020 · Frontiers in Cardiovascular Medicine
Cited by 96

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aim: This systematic review and meta-analysis aimed to investigate the risk of cardiovascular disease (CVD) and cerebrovascular disease (CeVD) events in women with polycystic ovary syndrome (PCOS). Methods: We searched the literatures in Pubmed, Embase, and Web of Science to identify the cohort studies reporting the association between PCOS and CVD/CeVD events from 1964 to June 1, 2020. Outcome variables such as all-cause mortality, cardiovascular death, any cardiovascular diseases, myocardial infarction, ischemic heart disease, and stroke are extracted from the identified literatures and reported the outcomes of the association in hazard ratios (HR) and odds ratios (OR). Results: Ten cohort studies comprising 166,682 samples are included in the review. Compared to non-PCOS women, the pooled risk of CVD events in PCOS women OR: 1.62 (95% CI: 1.34–1.97). In addition, the risk of myocardial infarction (OR: 2.57, 95% CI: 1.37–4.82), ischemic heart disease (OR: 2.77, 95% CI: 2.12–3.61), and stroke (OR: 1.96, 95% CI: 1.56–2.47) are higher in the PCOS group. However, no significant difference in the overall mortality (HR: 1.04, 95% CI: 0.57–1.86) and CVD-related death (HR: 1.49, 95% CI: 0.99–2.23) was observed. Funnel plots of all outcomes were roughly symmetric, and no significant publication bias was found. Conclusion: Through this study identified an increased risk of CVD and CeVD among women with PCOS including occurance of myocardial infarction, ischemic heart disease, and stroke, but no difference in the all cause or CVD related mortality observed. Further large scale studies are warranted to strengthen the association between PCOS and CV events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcvm.2020.552421

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 27

  1. Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 · DOI · Paper page
  2. Clayton, 1992, How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?, Clin Endocrinol, 37, 127, 10.1111/j.1365-2265.1992.tb02296.x · DOI · Paper page
  3. Cibula, 2000, Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome, Hum Reprod., 15, 785, 10.1093/humrep/15.4.785 · DOI · Paper page
  4. Kinoshita, 1990, Impaired glucose tolerance in patients with polycystic ovary syndrome (PCOS), Horm Res, 33, 18, 10.1159/000181560 · doi:10.1159/000181560
  5. Bedaiwy, 2018, Clinical, hormonal, and metabolic parameters in women with subclinical hypothyroidism and polycystic ovary syndrome: a cross-sectional study, J Women's Health., 27, 659, 10.1089/jwh.2017.6584 · DOI
  6. Vatopoulou, 2020, Management of obesity in adolescents with polycystic ovary syndrome. Expert Opin Pharmacother, 21, 1, 10.1080/14656566.2019.1701655 · DOI
  7. Jiang, 2019, Ceramide subclasses identified as novel lipid biomarker elevated in women with polycystic ovary syndrome: a pilot study employing shotgun lipidomics, Gynecol Endocrinol., 36, 1, 10.1080/09513590.2019.1698026 · DOI
  8. Jacewicz-Swiecka, 2018, Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies, Diabetes Metab Res Rev, 34, e3054, 10.1002/dmrr.3054 · DOI · Paper page
  9. Wang, 2012, Semiparametric hazard function estimation in meta-analysis for time to event data, Res Synth Methods, 3, 240, 10.1002/jrsm.1047 · DOI
  10. Greenland, 1987, Interpretation and choice of effect measures in epidemiologic analyses, Am J Epidemiol, 125, 761, 10.1093/oxfordjournals.aje.a114593 · DOI · Paper page
  11. Thompson, 1999, Explaining heterogeneity in meta-analysis: a comparison of methods, Stat Med, 18, 2693, 10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v · doi:10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v
  12. Calderon-Margalit, 2014, Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women's study, Arterioscler Thromb Vasc Biol, 34, 2688, 10.1161/ATVBAHA.114.304136 · DOI · Paper page
  13. Dahlgren, 1992, Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women, Acta Obstet Gynecol Scand, 71, 599, 10.3109/00016349209006227 · DOI · Paper page
  14. Ding, 2018, Coronary artery disease risk in young women with polycystic ovary syndrome, Oncotarget, 9, 8756, 10.18632/oncotarget.23985 · DOI
  15. Iftikhar, 2012, Risk of cardiovascular events in patients with polycystic ovary syndrome, Neth J Med., 70, 74
  16. Lo, 2006, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome, J Clin Endocrinol Metab, 91, 1357, 10.1210/jc.2005-2430 · DOI · Paper page
  17. Lunde, 2007, Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15–25 years after ovarian wedge resection, Gynecol Endocrinol, 23, 704, 10.1080/09513590701705189 · DOI · Paper page
  18. Mani, 2013, Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study, Clin Endocrinol, 78, 926, 10.1111/cen.12068 · DOI · Paper page
  19. Morgan, 2012, Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study, J Clin Endocrinol Metab, 97, 3251, 10.1210/jc.2012-1690 · DOI · Paper page
  20. Shaw, 2008, Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation, J Clin Endocrinol Metab, 93, 1276, 10.1210/jc.2007-0425 · DOI · Paper page
  21. Wild, 2000, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study, Hum Fertil., 3, 101, 10.1080/1464727002000198781 · DOI · Paper page
  22. Unluturk, 2007, The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-gamma, PPAR Res, 2007, 49109, 10.1155/2007/49109 · DOI · Paper page
  23. Alsamarai, 2009, Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age, J Clin Endocrinol Metab, 94, 4961, 10.1210/jc.2009-0839 · DOI · Paper page
  24. Armeni, 2019, Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome, Curr Vasc Pharmacol, 17, 579, 10.2174/1570161116666180828154006 · DOI
  25. Hernández-Reséndiz, 2018, Responses of endothelial cells towards ischemic conditioning following acute myocardial infarction, Cond Med., 1, 247
  26. Richardson, 2003, Current perspectives in polycystic ovary syndrome, Am Fam Physician, 68, 697
  27. Ueda-Nishimura, 2005, Synergic action of insulin and genistein on Na+/K+/2Cl- cotransporter in renal epithelium, Biochem Biophys Res Commun., 332, 1042, 10.1016/j.bbrc.2005.05.046 · DOI

Cited by

See all 96

Metadata

Authors
Zhang, J., Xu, J.-H., Qu, Q.-Q., & Zhong, G.-Q.
Venue
Frontiers in Cardiovascular Medicine
Published
2020-11-12
Volume
7
Pages
552421-552421
ISSN
2297-055X (ISSN-L)
OpenAlex
W3098746485
Cited by
96
References
18
FWCI
2.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.